替诺福韦相关性蛋白尿。
Tenofovir-associated proteinuria.
机构信息
Brisbane Sexual Health and HIV Service, Brisbane, Queensland, Australia.
出版信息
AIDS. 2013 Jan 28;27(3):479-81. doi: 10.1097/QAD.0b013e32835883bf.
Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year. Concomitant protease inhibitor therapy and cumulative tenofovir exposure were independently associated with proteinuria in this cohort. Proteinuria was reversible in 11 of 12 patients who ceased tenofovir because of proteinuria without altering other medications. Clinicians should be aware that tenofovir can cause reversible proteinuria in patients with HIV.
在 153 名接受替诺福韦治疗超过 1 年的患者中,有 27%出现蛋白尿。在该队列中,同时使用蛋白酶抑制剂治疗和累积替诺福韦暴露与蛋白尿独立相关。在因蛋白尿而停用替诺福韦且未改变其他药物的 12 名患者中的 11 名,蛋白尿是可逆的。临床医生应该意识到替诺福韦可能会导致 HIV 患者出现可逆性蛋白尿。